CDKN2 EXPLAINS PART OF THE CLINICAL PHENOTYPE IN DUTCH FAMILIAL ATYPICAL MULTIPLE-MOLE MELANOMA (FAMMM) SYNDROME FAMILIES

被引：89

作者：

GRUIS, NA ^{[1
]}

SANDKUIJL, LA ^{[1
]}

VANDERVELDEN, PA ^{[1
]}

BERGMAN, W ^{[1
]}

FRANTS, RR ^{[1
]}

机构：

[1] LEIDEN UNIV,MGC,DEPT HUMAN GENET,2300 RA LEIDEN,NETHERLANDS

来源：

MELANOMA RESEARCH | 1995年 / 5卷 / 03期

关键词：

CDKN2; FAMILIAL ATYPICAL MULTIPLE-MOLE MELANOMA SYNDROME; GERMLINE DELETION; MALIGNANT MELANOMA; LINKAGE ANALYSIS;

D O I：

10.1097/00008390-199506000-00005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Combined multi-point linkage analysis in seven Dutch families with FAMMM syndrome confirmed the location of a melanoma susceptibility (MLM) gene in the 9p21 area. The occurrence of a shared high-risk haplotype in six of the families strongly suggests a founder effect in the Leiden region. No indication for locus heterogeneity was observed. Recently, the CDKN2 (p16) gene, an important regulator of the cell cycle, was isolated from the 9p21 region. A 19-bp germline deletion in the CDKN2 gene was detected in the high-risk haplotype, suggesting CDKN2 to be identical to MLM. Loss of heterozygosity studies in melanoma and pancreatic carcinoma from gene carriers strongly support the view that CDKN2 is a general tumour suppressor gene predisposing not only to melanoma but also to other malignancies. Interestingly, the occurrence of apparent clinical FAMMM cases with melanoma but without the high-risk deletion haplotype suggests the necessity of additional (naevus) genes to explain the complete FAMMM phenotype.

引用

页码：169 / 177

页数：9

共 27 条

[1]

Bale S.J., Chakravarti A., Greene M.H., Cutaneous malignant melanoma and familial dysplastic nevi. Evidence for autosomal dominance and pleiotropy, Am J Hum Genet, 38, pp. 188-196, (1986)

[2]

Bergman W., Palan A., Went L.N., Clinical and genetic studies in six Dutch kindreds with the dysplastic naevus syndrome, Ann Hum Genet, 50, pp. 249-258, (1986)

[3]

Bale S.J., Dracopoli N.C., Greene M.H., Linkage analysis of melanoma and dysplastic nevus syndrome with polymorphic loci on human chromosome lp, Cytogenet Cell Genet, 46, (1987)

[4]

Risch N., Sherman S., Genetic Analysis Workshop 7: Summary of the melanoma workshop, Cytogenet Cell Genet, 59, pp. 148-158, (1992)

[5]

Cannon-Albright L.A., Goldgar D.E., Meyer L.J., Assignment of a locus for familial melanoma MLM, to chromosome 9p13-p22, Science, 258, pp. 1148-1152, (1992)

[6]

Kamb A., Gruis N.A., Weaver-Feldhaus J., A cell cycle regulator potentially involved in genesis of many tumour types, Science, 264, pp. 436-440, (1994)

[7]

Nobori T., Miura K., Wu D.J., Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers, Nature, 368, pp. 753-756, (1994)

[8]

Serrano M., Hannon G.J., Beach D., A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/ CDK4, Nature, 366, pp. 704-707, (1993)

[9]

Weaver-Feldhaus J., Gruis N.A., Neuhausen S., Localization of a putative tumor suppressor gene by using homozygous deletions in melanomas, Proc Natl Acad Sci USA, 91, pp. 7563-7567, (1994)

[10]

Gruis N.A., Weaver-Feldhaus J., Liu Q., Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression, Am J Pathol in Press

← 1 2 3 →